T herapeutic hypothermia has been around since antiquity. Hippocrates recommended packing wounded soldiers in snow and ice. Despite tremendous medical advances, the chances for meaningful survival after cardiac arrest are less than 30% due to the "postcardiac arrest syndrome" (1) . Therapeutic hypothermia is a medical intervention intended to reduce a patient's body temperature to 32-34°C, over a 6-to 8-hour period, in the attempt to reduce neurologic injury after a patient's resuscitation from cardiac arrest, newborn hypoxic ischemic encephalopathy, and possibly stroke. In pivotal clinical trials, targeted temperature management was achieved by surface cooling techniques or invasive core cooling measures. Noninvasive cooling techniques use various cold fluids that circulate through blankets, a torso vest, and leg wraps to achieve the desired temperature. Whereas, invasive techniques use intravascular cooling catheters containing metal coils or balloons filled with cold saline, in combination with cold saline infusions. Sedation, analgesia, and paralysis medications are given to the patient prior to inducing hypothermia to prevent shivering and minimize patient discomfort. The first major clinical trials to demonstrate direct evidence of a benefit of therapeutic hypothermia were published in 2002 and have widely been accepted as the basis for clinical guidelines and treatment protocols (2, 3) . Countless research endeavors tried to unlock the exact mechanism of neuroprotection at the cellular level, and a few common themes emerged.
The earliest hypothesis for the effects of hypothermia focused on reducing cellular metabolism. Researchers found that for every 1°C drop in core body temperature, the cellular metabolism is reduced by 5-7%. Therefore, it was thought that by lowering the core temperature one could reduce the harmful effects of ischemia and decrease the body's oxygen demand (4) . Additional theories focused on the relationship of cellular metabolism, glutamate production, and ion homeostasis. In animal models, researchers determined that stores of glucose and adenosine triphosphate are lost within 5 minutes after cardiac arrest. Substrate depletion quickly leads to the loss of transmembrane electrochemical gradients and sequential failure of synapse transmission, axonal conduction, and action potential firing. Consequently, it is not oxygen deprivation itself that is responsible for apoptosis, and cell death, but the inability to make ATP and maintain the cells homeostasis at normal body temperatures. Therapeutic hypothermia may also have neuroprotective effects in preventing reperfusion injury. Reoxygenation initiates chemical cascades producing free radicals that cause lipid peroxidation and other oxidative damage. Various inflammatory immune responses can cause endothelial activation, leukocyte migration, and further tissue injury or susceptibility to infection. Therefore, patients undergoing induction of hypothermia and the rewarming phase must be closely monitored to prevent undesired consequences. Clinicians must be vigilant to avoid overshooting the target temperature as the complications increase in severity, and the risk of adverse events increases at lower temperatures or with rapid fluctuations in the patient's core body temperature.
Adverse effects of therapeutic hypothermia can be a result of the cooling devices or hypothermia itself. Such events include increased bleeding, infection, deep venous thrombosis, and pulmonary edema (2, 3, 5) . In a 2009 study, Nielsen et al (6) conducted an observational study with 986 patients and demonstrated the following adverse effects: pneumonia (41%), hyperglycemia (37%), cardiac arrhythmias (33%), seizures (24%), and electrolyte disturbances (hypophosphatemia, 19%; hypomagnesemia, 18%; and hypokalemia, 18%). These safety issues bring us to this Critical Care Medicine issue, in which Geurts et al (7) performed a systematic review and meta-analysis to evaluate the risk of infections with the use of therapeutic hypothermia. They included 23 randomized trials with a total of 2,820 patients and showed that the overall prevalence of all infections was associated with a nonsignificant 21% increase in infections, but when the authors analyzed the data by specific types of infections, they found a significant 44% increase in the risk of pneumonia and a 80% increase in the risk of sepsis with the use of therapeutic hypothermia. Further, a dose-effect www.ccmjournal.org
February 2014 • Volume 42 • Number 2 I n 1996, the Institute for Healthcare Improvement suggested implementation of rapid response teams (RRTs) as one of six recommended strategies to prevent inpatient deaths (1). This concept, initially applied to adult care, has now become the standard of practice in pediatric hospitals (2-4). Many pediatric hospitals are now striving to advance the performance of RRTs to improve early intervention and ultimately prevent pediatric arrests (3, (5) (6) (7) (8) (9) .
Over the past 15 years, cardiopulmonary resuscitation (CPR) effectiveness has also been studied aggressively (10-12). According to 2008 data from the National Registry of Cardiopulmonary Resuscitation, survival rates as high as 33% have been seen with inpatient pediatric pulseless arrest. Not surprisingly, children and infants who received interventions prior to progression to arrest had a 64% survival to discharge (10). Improved RRT performance may help to bolster these needed interventions and therefore yield improved outcomes.
was also seen, that is, the more prolonged the cooling time, the higher the risk for infections. This meta-analysis was well performed from the methodological perspective but limitations of the original trials are important as the authors recognized in the article: "the risk of bias in the included studies was high because information on the method of randomization and definitions of infections lacked in most cases, and assessment of infections was not blinded." Also concerning is the fact that the authors had to exclude 31 randomized trials with 4,004 patients because they did not report any quantitative data on infection complications! Hence, underreporting of infection complications is very likely. This finding in combination with the authors' results indicating higher risk of pneumonia and sepsis is definitely relevant because they suggest that we still do not know the actual risk of infection, which could be even higher than the one found in this new meta-analysis. Is there a biological rationale for the increased risk for infections? Yes, hypothermia alters the cytokine dynamics, reducing proinflammatory cytokines and inhibiting leukocyte migration and phagocytosis, all of which could be involved in the higher propensity for infections (8) . Whether prophylactic antibiotics should be used, or even if they would have any efficacy in the setting of substantial vasoconstriction and altered pharmacokinetic and pharmacodynamic properties during hypothermia, remains to be defined in future studies.
The findings from the meta-analysis by Geurts et al (7) are pertinent for both clinicians and researchers: they establish that hypothermia is in fact associated with a significant higher risk of pneumonia and sepsis (clinical awareness) and that all clinical trials on therapeutic hypothermia must perform the systematic collection of infection data (research awareness) as part of their design, case report form, and statistical plan to report this indispensable safety analysis.
